Antisense And RNAi Therapeutics Market- By Technology (RNA Interference, Antisense RNA), By Route Of Administration (Intravenous injections, Intra Dermal injunctions, Other delivery methods), By Indication (Oncology, Cardiovascular device, Respiratory disorders, Neurological disorders, Infectious disease, Other diseases), And By Region, Opportunities And Strategies – Global Forecast To 2030
$
4000.00
February 2021
Antisense & RNAi Therapeutics Market Definition
The antisense and RNAi therapeutics market consists of sales of antisense and RNAi therapeutics by entities (organizations, sole traders, and partnerships) that develop and manufacture antisense and RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various diseases including cancer, infectious diseases, cardiovascular diseases, genetic disorders, respiratory disorders, and neurological disorders.
Two major methods are employed in RNA therapeutics: double stranded RNA-mediated interference (RNAi) and antisense oligonucleotides (ASO). Both these methods differ in composition and modes of action. These antisense oligonucleotides and siRNAs mainly target the ribonucleic acid (RNA), whereas small molecules and biologic drugs primarily target proteins due to their chemical properties and distinct molecular mechanism of action.
Telemedicine Services Market - By Technology (Real Time, Store and Forward), By Application (Telecardiology, Telepsychiatry, Teledermatalogy, Teleradiology, Telepathology, Other Telemedicine Services) And By Region, Opportunities And Strategies – Global Forecast To 2030
$
6000.00
December 2020
Telemedicine Services Market Definition
The telemedicine services market consists of sale of telemedicine services and related products. Telemedicine services are healthcare services provided via video chats, phone calls, and text messages. Patients can use telemedicine for physical examinations as well as to ask questions regarding health concerns. Telemedicine services are offered by healthcare professionals via various information and communication technologies with the aim of exchanging valid information for the diagnosis, treatment and prevention of diseases and injuries in patients where distance is a critical factor.
Human Microbiome Therapeutics Market - By Disease (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers, Other Diseases), By Sequencing Technology Type (Targeted Gene, RNA, Whole-Genome Shotgun (WGS), Others Type) And By Region, Opportunities And Strategies – Global Forecast To 2030
$
4000.00
December 2020
Human Microbiome Therapeutics Market Definition
The human microbiome therapeutics market consists of sales of microbiome and related services used as immunotherapeutic agents in the pharmaceutical industry. Microbiomes are used as immunotherapy for a wide variety of conditions, including infectious diseases, endocrine & metabolic disorders, inflammatory conditions, cancers, irritable bowel syndrome, neurological disorders, hematological disorders and cardiovascular diseases.
The microbiome consists of the genetic material within a microbiota, which is the collection of microorganisms, such as bacteria, archaea, fungi, and viruses, in a specific niche, such as the human gut. For example, the gut microbiome consists of collective genome of microbes inhabiting the gut. Microbiomes are also known as the metagenome of the microbiota.
Global Biologics Market - By Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), By Route Of Administration (Oral, Others (IV or IP)), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription Drugs, OTC Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2023
$
6000.00
December 2020
Biologics Market Definition
The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics or biosimilars to treat and prevent various microbial diseases and cancers. The biologics market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics.
Biologics products are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy and marketing. Biologics products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies. Biosimilars should have similar safety and efficacy compared to the reference biologic product. The biologics market comprises of biologics and biosimilar drugs through oral, IV and other delivery routes for the treatment of chronic diseases.
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
$
4000.00
November 2020
CAR-T Therapy Market Definition
The chimeric antigen receptor -T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat blood cancers.
CAR-T therapy is type of immunotherapy in which T-cells taken from patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs.
Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030
$
4000.00
$3200.00
August 2020
Oral Biologics & Biosimilars Market Definition
The oral biologics and biosimilars market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, and cancer.
Biologics are drugs made from living cells using highly complex technology, while biosimilars are biological products which are being produced to be identical to a biologic already approved, known as reference drugs. Biosimilars should have similar safety and efficacy compared to the reference biologic product. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs through oral delivery route, for the treatment of chronic diseases.
